AMGN vs. BMY: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at AMGN and BMY, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
AMGN dominates in value with a market cap of 145.90 billion USD, eclipsing BMY’s 95.26 billion USD by roughly 1.53×.
With betas of 0.50 for AMGN and 0.40 for BMY, both show similar volatility profiles relative to the overall market.
| Symbol | AMGN | BMY |
|---|---|---|
| Company Name | Amgen Inc. | Bristol-Myers Squibb Company |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| CEO | Mr. Robert A. Bradway | Dr. Christopher S. Boerner Ph.D. |
| Price | 271.34 USD | 46.81 USD |
| Market Cap | 145.90 billion USD | 95.26 billion USD |
| Beta | 0.50 | 0.40 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 17, 1983 | June 1, 1972 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of AMGN and BMY over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of AMGN and BMY based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- BMY shows a negative forward PEG of -3.01, signaling expected earnings contraction, while AMGN at 7.08 maintains analysts’ projections for stable or improved profits.
| Symbol | AMGN | BMY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 24.60 | 17.54 |
| Forward PEG Ratio (TTM) | 7.08 | -3.01 |
| Price-to-Sales Ratio (P/S, TTM) | 4.28 | 2.00 |
| Price-to-Book Ratio (P/B, TTM) | 23.52 | 5.47 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 13.37 | 7.28 |
| EV-to-EBITDA (TTM) | 15.71 | 8.38 |
| EV-to-Sales (TTM) | 5.70 | 2.85 |
| EV-to-Free Cash Flow (TTM) | 17.82 | 10.36 |
Dividend Comparison
BMY stands out with a 5.21% dividend yield—around 53% above AMGN’s 3.41%—highlighting its emphasis on generous payouts.
| Symbol | AMGN | BMY |
|---|---|---|
| Dividend Yield (TTM) | 3.41% | 5.21% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of AMGN and BMY, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- AMGN is heavily leveraged (debt-to-equity ratio 9.24), which can boost returns but raises risk if borrowing costs climb, while BMY at 2.95 keeps leverage at a more moderate level.
| Symbol | AMGN | BMY |
|---|---|---|
| Current Ratio (TTM) | 1.17 | 1.28 |
| Quick Ratio (TTM) | 0.88 | 1.17 |
| Debt-to-Equity Ratio (TTM) | 9.24 | 2.95 |
| Debt-to-Assets Ratio (TTM) | 0.64 | 0.55 |
| Interest Coverage Ratio (TTM) | 3.19 | 4.36 |